<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883814</url>
  </required_header>
  <id_info>
    <org_study_id>182-20-CA</org_study_id>
    <nct_id>NCT04883814</nct_id>
  </id_info>
  <brief_title>18F-fluoroestradiol (FES) PET/CT for Breast Cancer</brief_title>
  <official_title>18F-fluoroestradiol (FES) PET/CT Compared To Standard-of-Care Imaging In Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoag Memorial Hospital Presbyterian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoag Memorial Hospital Presbyterian</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard of care imaging of breast cancer metastases recommended by the National&#xD;
      Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be&#xD;
      suboptimal. 18F-fluoroestradiol (FES) is a novel PET tracer designed to detect estrogen&#xD;
      receptors, which are often expressed in breast cancers. FES PET/CT may provide improved&#xD;
      evaluation of metastases in patients with ER-positive breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a phase II clinical trial to assess the clinical value of FES for staging and&#xD;
      detection of disease recurrence in patients with ER-positive breast cancer, in direct&#xD;
      comparison to the National Comprehensive Cancer Network's (NCCN) recommended standard-of-care&#xD;
      using CT of the chest/abdomen/pelvis and bone scan [2].&#xD;
&#xD;
      Two cohorts will be evaluated:&#xD;
&#xD;
        1. Patients with advanced local breast cancer that will undergo standard of care imaging&#xD;
           (CT + bone scan) to evaluate for unsuspected distant metastases.&#xD;
&#xD;
        2. Patients with suspicion for breast cancer recurrence that will undergo standard of care&#xD;
           imaging (CT + bone scan) to evaluate for disease recurrence.&#xD;
&#xD;
      In both cohorts, FES PET/CT will be obtained, and compared with standard of care imaging.&#xD;
      Whether on standard of care imaging or the research FES PET/CT, lesions suspicious for&#xD;
      unsuspected distant metastases (cohort 1) or the site of disease recurrence (cohort 2) will&#xD;
      be selected for biopsy, as is clinically standard of care to confirm disease that would alter&#xD;
      patient management. Pathology will be used as the reference standard for confirming&#xD;
      malignancy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of unsuspected distant metastases</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>FES PET/CT will be compared against standard of care CT/bone scan for detection of unsuspected distant metastases in patients with ER+ locally advanced disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of suspected disease recurrence</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>FES PET/CT will be compared against standard of care CT/bone scan for detection of unsuspected distant metastases in patients with ER+ breast cancer and suspected disease recurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Initial Staging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FES PET/CT will be compared to CT/bone scan for detection of unsuspected distant metastases in patients with ER-positive locally advanced breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suspected disease recurrence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FES PET/CT will be compared to CT/bone scan for detection of unsuspected distant metastases in patients with ER-positive breast cancer and suspected disease recurrence</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F-fluoroestradiol PET/CT</intervention_name>
    <description>Estrogen receptor targeted imaging</description>
    <arm_group_label>Initial Staging</arm_group_label>
    <arm_group_label>Suspected disease recurrence</arm_group_label>
    <other_name>FES PET/CT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female â‰¥ 18 years of age.&#xD;
&#xD;
          2. Histologically confirmed ER-positve breast cancer. Any pathology from a primary or&#xD;
             metastatic breast cancer site demonstrating ER-positivity will be allowed.&#xD;
&#xD;
          3. ECOG performance status 0 to 2&#xD;
&#xD;
          4. Written informed consent (and assent when applicable) obtained from subject or&#xD;
             subject's legal representative and ability for subject to comply with the requirements&#xD;
             of the study.&#xD;
&#xD;
          5. Either:&#xD;
&#xD;
               1. For cohort 1: Stage 2B-3C locally advanced disease and plan for CT/bone scan&#xD;
                  systemic staging or&#xD;
&#xD;
               2. For cohort 2: Suspected recurrent disease and plan for CT/bone scan systemic&#xD;
                  staging&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding&#xD;
&#xD;
          2. Presence of a condition or abnormality that in the opinion of the Investigator would&#xD;
             compromise the safety of the patient or the quality of the data.&#xD;
&#xD;
          3. Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners&#xD;
             may not be able to function with patients over 450 pounds.&#xD;
&#xD;
          4. Selective ER Modulators (SERMs) such as tamoxifen and Selective ER Degraders (SERDs)&#xD;
             such as fulvestrant may reduce detection of ER-positive lesions by FES. Thus,&#xD;
             exclusion criteria specify that patients must be withdrawn from Selective ER Modifiers&#xD;
             for at least 8 weeks and withdrawn from Selective ER Degraders for for least 24 weeks&#xD;
             prior to performance of the FES PET/CT.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Ulaner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hoag Family Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Thomsen</last_name>
    <phone>949-764-4577</phone>
    <email>clinicalresearch@hoag.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gary Ulaner, MD, PhD</last_name>
    <phone>949-577-0252</phone>
    <email>gary.ulaner@hoag.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Thomsen</last_name>
      <email>beth.thomsen@hoag.org</email>
    </contact>
    <investigator>
      <last_name>Gary Ulaner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hoag Memorial Hospital Presbyterian</investigator_affiliation>
    <investigator_full_name>Gary Ulaner</investigator_full_name>
    <investigator_title>Director Molecular Imaging and Therapy</investigator_title>
  </responsible_party>
  <keyword>18F-fluoroestradiol</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>PET/CT</keyword>
  <keyword>Staging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

